ANAVEX. NY TRÅD NY TRÅD over 100 % indrulning i Alzheimer!
-
Tasso og solsen hvorfor så ikke vente til de sidste nyheder er offentliggjort? Jeg er udmærket klar over at de skal bruge penge, det er ikke det jeg anfægter. Æv
-
Anavex Rettelse SAVA og ANVS!
SAVA hentede i feb. 2021 200 mill. til kurs 49 $ - i dag har de kurs 90 $.
Cassava Sciences Announces Closing of $200 Million Registered Direct Offering
AUSTIN, Texas, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the closing of its previously announced registered direct offering of 4,081,633 shares of its common stock, at a purchase price per share of $49.00, for gross proceeds of approximately $200.0 million. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The net proceeds of the offering are estimated to be approximately $189.7 million, after deducting placement agent fees and other estimated offering expenses. Cassava Sciences intends to use the net proceeds from this offering for working capital and general corporate purposes, including development of simufilam, the Company’s lead drug candidate for the treatment of Alzheimer’s disease. The shares of common stock were offered by Cassava Sciences pursuant to an automatic "shelf" registration statement on Form S-3, which was filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 10, 2021 and became effective immediately upon filing, and the base prospectus contained therein. The offering was made only by means of a prospectus supplement that forms a part of the registration statement. A final prospectus supplement and accompanying base prospectus relating to the shares of common stock being offered was filed with the SEC. Copies of the final prospectus supplement and accompanying base prospectus may be obtained on the SEC's website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at 646-975-6996 or e-mail at [email protected]. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction. About Cassava Sciences, Inc.Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer’s disease. For More Information Contact:Eric Schoen, Chief Financial OfficerCassava Sciences, [email protected](512) 501-2450 Forward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements may include, without limitation, statements regarding (i) the estimated net proceeds and the use of proceeds of the registered direct offering, and (ii) the assumptions underlying or relating to any statement under clause (i). Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of those risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, unfavorable market conditions, occurrence of force majeure, the Company’s inability to obtain adequate financing to fund its operations and necessary to develop or enhance its products, the Company’s ability to conduct or complete clinical studies on expected timelines, the Company’s ability to demonstrate the specificity, safety, efficacy or potential health benefits of its product candidates, the severity and duration of health care precautions given the COVID-19 pandemic and unanticipated impacts of the pandemic on the Company’s business operations. These and other risk factors are identified and described in more detail in the prospectus supplement filed with the SEC in connection with the offering, including the Company’s most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report on Form 10-Q, which are incorporated by reference in such prospectus supplement, and the other documents incorporated by reference in such prospectus supplement and Company’s other filings with the SEC. The Company does not undertake to update these forward-looking statements.
Yahoo Finance (finance.yahoo.com)
ANVS hentede i maj 2021 50 mill. til kurs 50 $ - i dag har de kurs 96 $.
https://finance.yahoo.com/news/annovis-bio-inc-announces-closing-155500148.html
Salget af de godt 2,4 mill. aktier svarer til en "udvanding" på kun ca. 3 % eller 0,75 $ ifht. kurs 25 $!
Men denne "udvanding" polstre jo kassen med gode 50 mill. $ - værdierne er jo ikke fjernet fra selskabet!
Mange andre sunde erhvervsselskaber tager jo også f.eks lån for at vokse/udvikle.
Genmab undlader f.eks. at udbetale store afkast til investorerne for at putte pengene i udvikling.Annovis Bio, Inc. Announces Closing of $50 Million Public Offering
Berwyn, Pennsylvania--(Newsfile Corp. - May 27, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the closing of its underwritten public offering of 1,000,000 shares of its common stock at a public offering price of $50.00 per share, for gross proceeds of $50,000,000, before deducting underwriting discounts, commissions and offering expenses. All of ...
Yahoo Finance (finance.yahoo.com)
Er overbevist om, at vi min. vil se tilsvarende kursudvikling som i SAVA og ANVS - så ro på - skidtet virker jo har vi lige set!
-
Anavex Rettelse SAVA og ANVS!
Ved ikke lige hvad der skete?
SAVA hentede i feb. 2021 200 mill. til kurs 49 $ - i dag har de kurs 90 $.
Cassava Sciences Announces Closing of $200 Million Registered Direct Offering
AUSTIN, Texas, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the closing of its previously announced registered direct offering of 4,081,633 shares of its common stock, at a purchase price per share of $49.00, for gross proceeds of approximately $200.0 million. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The net proceeds of the offering are estimated to be approximately $189.7 million, after deducting placement agent fees and other estimated offering expenses. Cassava Sciences intends to use the net proceeds from this offering for working capital and general corporate purposes, including development of simufilam, the Company’s lead drug candidate for the treatment of Alzheimer’s disease. The shares of common stock were offered by Cassava Sciences pursuant to an automatic "shelf" registration statement on Form S-3, which was filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 10, 2021 and became effective immediately upon filing, and the base prospectus contained therein. The offering was made only by means of a prospectus supplement that forms a part of the registration statement. A final prospectus supplement and accompanying base prospectus relating to the shares of common stock being offered was filed with the SEC. Copies of the final prospectus supplement and accompanying base prospectus may be obtained on the SEC's website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at 646-975-6996 or e-mail at [email protected]. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction. About Cassava Sciences, Inc.Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer’s disease. For More Information Contact:Eric Schoen, Chief Financial OfficerCassava Sciences, [email protected](512) 501-2450 Forward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements may include, without limitation, statements regarding (i) the estimated net proceeds and the use of proceeds of the registered direct offering, and (ii) the assumptions underlying or relating to any statement under clause (i). Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of those risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, unfavorable market conditions, occurrence of force majeure, the Company’s inability to obtain adequate financing to fund its operations and necessary to develop or enhance its products, the Company’s ability to conduct or complete clinical studies on expected timelines, the Company’s ability to demonstrate the specificity, safety, efficacy or potential health benefits of its product candidates, the severity and duration of health care precautions given the COVID-19 pandemic and unanticipated impacts of the pandemic on the Company’s business operations. These and other risk factors are identified and described in more detail in the prospectus supplement filed with the SEC in connection with the offering, including the Company’s most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report on Form 10-Q, which are incorporated by reference in such prospectus supplement, and the other documents incorporated by reference in such prospectus supplement and Company’s other filings with the SEC. The Company does not undertake to update these forward-looking statements.
Yahoo Finance (finance.yahoo.com)
ANVS hentede i maj 2021 50 mill. til kurs 50 $ - i dag har de kurs 96 $.
https://finance.yahoo.com/news/annovis-bio-inc-announces-closing-155500148.html
Salget af de godt 2,4 mill. aktier svarer til en "udvanding" på kun ca. 3 % eller 0,75 $ ifht. kurs 25 $!
Men denne "udvanding" polstre jo kassen med gode 50 mill. $ - værdierne er jo ikke fjernet fra selskabet!
Mange andre sunde erhvervsselskaber tager jo også f.eks lån for at vokse/udvikle.
Genmab undlader f.eks. at udbetale store afkast til investorerne for at putte pengene i udvikling.Annovis Bio, Inc. Announces Closing of $50 Million Public Offering
Berwyn, Pennsylvania--(Newsfile Corp. - May 27, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the closing of its underwritten public offering of 1,000,000 shares of its common stock at a public offering price of $50.00 per share, for gross proceeds of $50,000,000, before deducting underwriting discounts, commissions and offering expenses. All of ...
Yahoo Finance (finance.yahoo.com)
Er overbevist om, at vi min. vil se tilsvarende kursudvikling som i SAVA og ANVS - så ro på - skidtet virker jo har vi lige set!
-
Det er sådan at nye investorer gerne vil se der er mulighed for et godt afkast også på kort sige.
Så hvis alle de gode nyheder var brændt af var det jo ikke så interessant.
Men vi er trods alt i kurs 21
Jeg skal ikke afvise at der også er en vis rettidigt omhu i udvidelsen nu, da man jo ikke er 100% sikker på fremtiden i biotech og markedet generelt.
De Peer review artikler vi venter på tror jeg ikke man kan styre udgivelsestidspunktet af på kort sigt. Og jeg vil forvente, at man meget snart går i afsluttende forhandling med en stor partner på PDD - derfor skal man ikke være fattig, når man sidder ved det bord da det svækker forhandlingskraften
-
Anavex Dirct offering!
Min opfattelse af situationen:
Via H.C. Wainwrigh, henvender der sig en større og seriøs investor, der ønsker en større potion aktier i Anavex.
Anavex og denne investor mødes og investoren får her en god snak med Missling om potentialet i Anavex og bliver enig om betingelserne omkring investeringen.
Ved at få en større og seriøs investor ind, der måske også lover yderligere opkøb på alm. markeds forhold, får Anavex penge i kassen og en der har både et incitament til at vidneskaben skal lykkes og samtidig få en økonomisk gevinst og en helt normal rabat ved et køb af en større portion aktier.
( En del af spillet )
Alternativet er salg af aktier i det fri markedet som hidtil, hvor Anavex ikke har styr på, hvem der køber - trader/kortsigtede investorer, short m.m.Vi har lige fået bekræftet, at 2-73 virker i min. RETT og sandsynligvis til et bredt spectre af CNS indikationer - og vi har tidligere set super gode og hidtil usete topline resultater i PDD.
Med Misslings helt sikker kendskab til de kommende Peer Reviews i tankerne, tror jeg simpelthen ikke på, at Missling ville lokke eller vildlede en potentiel større investor til at gå ind i Anavex!!
Missling ville aldrig kunne lokke andre seriøse investor til, hvis han umiddelbar efter ville smide dårlige resultater på bordet.Dette har bare styrket min tro på gode resultater og Peer Reviews - og tror som minimum, at vi som ved SAVA og ANVS vil se en fordobling af kursen på Anavex til 45-50 $ inden for den næste mdr. eller 2.
-
Vi har kun problemet i denne tråd. Jeg har ikke oplevet det før. Alle indlæg kan dog læses. Ryk dem ind med curseren. Vores tekniker ser på det senere.
PS: Trafikken og antal besøgende er faktisk vanvittig stor på tråden i disse dage. -
kan vi ikke bare lave en tråd så ????
-
Det må brugerne selv om. De plejer at lave nye, når de gamle bliver alt for lange. Min tekniker arbejder på problemet i denne.
-
Ticker: SAVA man skulle tro det var SAVA der vil hente penge i marked -14% det nok frygten for at de kommer til at skulle hente langt flere penge, da de jo ikke er i nærheden af hvor AVXL er nu... pipelinen koster bare kassen med alle diverse forsøg, SAVA burde vel ikke have en kurs på 77$ hvis du spørger mig, nærmere 35$
Lagt en ny ordre ind på 23,3.... Det muligt den går under, men et skud værd...
-
Mere god omtale af AVXL:
TDT123:Jeg forstår overhovet heller ikke den værdi af SAVA & ANVS selvom vi medregner udestående aktier, de gir et lille pip fra sig og kursen flyver i vejret.
Jeg synes også at det ser mægtigt godt ud for Anavex, PDD data afventet med stor stor spænding og hvis de er som vi regner/håber på så er vi næsten i mål men selvfølgelig ikke over målstregen før noget er godkendt.
-
Tråden fungerer igen.
-
Anavex Lidt mere omtale - 5 MOST PROMISING ALZHEIMER'S DISEASE STOCK.
5 Most Promising Alzheimer’s Disease Stock!
Top equity research firm that authors institutional quality equity research reports, with special focus on undervalued Micro-Cap stocks that lacks adequate coverage.
Avise Analytics | we value your company (www.aviseanalytics.com)
Transaktionen med de 50 mill. $ forventes afsluttet i morgen den 24. juni - måske venter Anavex med nyheder efter dette er afsluttet.
ANVS kom med gode nyheder 2 dage efter de ligeledes hentede 50 mill. $ på tilsvarende måde.Igen - nægter simpelthen at tro på, at Anavex ville komme med dårlige nyheder efter at have kigget en ny stor investor i øjnene og forsikret dem om, at de trygt kan betale 21 $ pr. aktie!
Forventer endnu bedre og signifikante PDD resultater og positiv påvirkning af kursen - både pga. et mere robust forsøg med 120 ( 14 uger ), mod RETTs ( 7 uger ) 31 personer.
Samtidig ved alle hvad Parkinson er, modsat det mere ukendte RETT. -
Anavex Deep Track Capital er den nye storinvestor!
Anavex har nu sat navn på den større investor, der er gået ind i Anavex med 50 mill. $ 2,380,953 aktier/kurs 21$.
Tror umiddelbar ikke de kunne have fundet en bedre investor/partner.
Deep Track Capital stiller ikke kun med en kapital indsprøjtning, men stiller hele deres netværk og ekspertise til rådighed.
Dette er ikke bare en investor, der vil have en hurtig profit, men mere en partner, der vil forsøge at bidrage på alle niveauer til at Anavex kan få succes.
Dette er en meget mere afgørende/vigtig nyhed, end det bliver afspejlet i markedet!Ingen ved deres fulde fem kan nu tro på, at Anavex underløber en sådan partner, ved at komme med dårlige resultater umiddelbar efter at samarbejdet er indgået!
Dette er for mig en vink med en vognstang, at Anavex har virkelige gode resultater på vej - og at de nu har fundet en seriøs partner, der kender spillet og kan tilfører viden og netværk til at skyde bolden helt i mål - uden at måtte dele guldet med en evt. større BP partner.
Tror endda, at Anavex lige gerne ville have denne aftale på plads inden de serverer gode resultater fra PDD m.m.
Vi andre investorer har jo også nu haft mulighed for at agerer på denne aftale - for hvis en investor tør smide 50 mill. $ ind i Anavex lige før ventede og afgørende resultater, så har vi andre og nye investorer nu også haft muligheden for at gøre det samme.Hvis jeg var en kapitalfond eller anden større investeringsselskab, ville jeg måske også stille mig det spørgsmål - hvad har Deep Track Capital fået af viden/indsigt, siden de tør smide 50 mill. $ ind nu???
Deep Track Capital which Deep Track Capital is a Greenwich, Connecticut-based investment firm focused exclusively on the life sciences industry. We develop long term partnerships with management teams of leading innovative public and pre-IPO biotechnology companies. In addition to capital, we seek to invest our time and expertise, while leveraging our network for the benefit of our partners. We aim to lead transactions while building large syndicates, and also to invest in rounds led by other qualified investors.
Who We Are — Deep Track Capital
Deep Track Capital is a Greenwich, Connecticut-based investment firm focused exclusively on the life sciences industry.
Deep Track Capital (www.deeptrackcapital.com)
-
Lyder godt det der, meget godt. Okay, Missling kan ikke skalte og valte med færdige analyser som det passer firmaet bedst, men for søren hvor jeg håber det lykkes det her. Der ligger en video på MB Yahoo, vil ikke poste den, men den er GODT nok positiv smiley. Varer ikke længe før shortersvinene giver op.
Tak for info Tasso -
Anavex Er det denne video MM? - udgivet i dag!
Kender intet til udgiveren, men han giver faktisk et meget godt overblik over Anavex casen.
Så for den nye potentielle investor, der måske aldrig tidligere har hørt om Anavex og deres tilgang, er dette en ganske udmærket introduktion.Millionaires Investment Secrets har tilsyneladende 94.600 abonnenter og videoen er blevet set 4225 gange i dag.
- ringe i vandet!!!
Lidt vildt, hvis os gl. Anavex nørder, med et nok meget "pænt" afkast indtil videre, måske er vidne til, at største delen af markedet først nu opdager vores guldklump - og selv fra nuværende kurs ser store mulighed for et stort fremtidig afkast.
-
Ja det er den.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind